Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Polman, CH' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 107 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. van der Vliet, HJJ; von Blomberg, BME; Nishi, N; Reijm, M; Voskuyl, AE; van Bodegraven, AA; Polman, CH; Rustemeyer, T; Lips, P; van den Eertwegh, AJM; Giaccone, G; Scheper, RJ; Pinedo, HM
      Circulating V alpha 24(+) V beta 11(+) NKT cell numbers are decreased in awide variety of diseases that are characterized by autoreactive tissue damage

      CLINICAL IMMUNOLOGY
    2. Hoogervorst, ELJ; Kalkers, NF; van Winsen, LML; Uitdehaag, BMJ; Polman, CH
      Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis

      MULTIPLE SCLEROSIS
    3. Boringa, JB; Lazeron, RHC; Reuling, IEW; Ader, HJ; Pfennings, LEMA; Lindeboom, J; de Sonneville, LMJ; Kalkers, NF; Polman, CH
      The Brief Repeatable Battery of Neuropsychological Tests: normative valuesallow application in multiple sclerosis clinical practice

      MULTIPLE SCLEROSIS
    4. Killestein, J; Den Drijver, BF; Van der Graaff, WL; Uitdehaag, BMJ; Polman, CH; Van Lier, RAW
      Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease

      MULTIPLE SCLEROSIS
    5. Uitdehaag, BMJ; Hoekstra, K; Koper, JW; Polman, CH; Dijkstra, CD
      IFN-beta 1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    6. Polman, CH; Uitdehaag, BMJ
      Drug treatment of multiple sclerosis - Clinical review was unsystematic - Reply

      BRITISH MEDICAL JOURNAL
    7. van Veen, T; Crusius, JBA; Schrijver, HM; Bouma, G; Killestein, J; van Winsen, L; Pena, AS; Polman, CH; Uitdehaag, BMJ
      Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis

      ANNALS OF NEUROLOGY
    8. McDonald, WI; Compston, A; Edan, G; Goodkin, D; Hartung, HP; Lublin, FD; McFarland, HF; Paty, DW; Polman, CH; Reingold, SC; Sandberg-Wollheim, M; Sibley, W; Thompson, A; van den Noort, S; Weinshenker, BY; Wolinsky, JS
      Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

      ANNALS OF NEUROLOGY
    9. van der Bruggen, MAM; Huisman, HBM; Beckerman, H; Bertelsmann, FW; Polman, CH; Lankhorst, GJ
      Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury

      JOURNAL OF NEUROLOGY
    10. van Boxel-Dezaire, AHH; Smits, M; van Trigt-Hoff, SCJ; Killestein, J; van Houtwelingen, JC; Polman, CH; Nagelkerken, L
      Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis

      JOURNAL OF NEUROIMMUNOLOGY
    11. Killestein, J; Rep, MHG; Barkhof, F; Roos, MTL; Ader, HJ; van Lier, RAW; Polman, CH
      Active MRI lesion appearance in MS patients is preceded by fluctuations incirculating T-helper 1 and 2 cells

      JOURNAL OF NEUROIMMUNOLOGY
    12. Kalkers, NF; Bergers, E; Castelijns, JA; van Walderveen, MAA; Bot, JCJ; Ader, HJ; Polman, CH; Barkhof, F
      Optimizing the association between disability and biological markers in MS

      NEUROLOGY
    13. Killestein, J; Kalkers, NF; Meilof, JF; Barkhof, F; van Lier, RAW; Polman, CH
      TNF alpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS

      NEUROLOGY
    14. Hoogervorst, ELJ; van Winsen, LML; Eikelenboom, MJ; Kalkers, NF; Uitdehaag, BMJ; Polman, CH
      Comparisons of patient self-report, neurologic examination, and functionalimpairment in MS

      NEUROLOGY
    15. Morre, SA; van Beek, J; De Groot, CJA; Killestein, J; Meijer, CJLM; Polman, CH; van der Valk, P; Middeldorp, JM; van den Brule, AJC
      Is Epstein-Barr virus present in the CNS of patients with MS?

      NEUROLOGY
    16. Kalkers, NF; Bergers, L; de Groot, V; Lazeron, RHC; van Walderveen, MAA; Uitdehaag, BMJ; Polman, CH; Barkhof, F
      Concurrent validity of the MS functional composite using MRI as a biological disease marker

      NEUROLOGY
    17. Kalkers, NF; Hintzen, RQ; van Waesberghe, JHTM; Lazeron, RHC; van Schijndel, RA; Ader, HJ; Polman, CH; Barkhof, B
      Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (vol 184, pg 155, 2001)

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    18. Kalkers, NF; Hintzen, RQ; van Waesberghe, JHTM; Lazeron, RHC; van Schijndel, RA; Ader, HJ; Polman, CH; Barkhof, F
      Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    19. De Groot, CJA; Bergers, E; Kamphorst, W; Ravid, R; Polman, CH; Barkhof, F; van der Valk, P
      Post-mortem MRI-guided sampling of multiple sclerosis brain lesions - Increased yield of active demyelinating and (p)reactive lesions

      BRAIN
    20. Barkhof, F; van Waesberghe, JHTM; Filippi, M; Yousry, T; Miller, DH; Hahn, D; Thompson, AJ; Kappos, L; Brex, P; Pozzilli, C; Polman, CH
      T-1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment

      BRAIN
    21. Nijeholt, GJLA; Bergers, E; Kamphorst, W; Bot, J; Nicolay, K; Castelijns, JA; van Waesberghe, JHTM; Ravid, R; Polman, CH; Barkhof, F
      Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis -A correlative study with conventional MRI, histopathology and clinical phenotype

      BRAIN
    22. van Walderveen, MAA; Lycklama a Nijeholt, GJ; Ader, HJ; Jongen, PJH; Polman, CH; Castelijns, JA; Barkhof, F
      Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging - Relation to clinical characteristics in subgroups of patients with multiplesclerosis

      ARCHIVES OF NEUROLOGY
    23. Arnoldus, JHA; Killestein, J; Pfennings, LEMA; Jelles, B; Uitdehaag, BMJ; Polman, CH
      Quality of life during the first 6 months of interferon-beta treatment in patients with MS

      MULTIPLE SCLEROSIS
    24. Tan, IL; Lycklama a Nijeholt, GJ; Polman, CH; Ader, HJ; Barkhof, F
      Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

      MULTIPLE SCLEROSIS
    25. Nijeholt, GJLA; Castelijns, JA; Lazeron, RHC; van Waesberghe, JHTM; Polman, CH; Uitdehaag, BMJ; Barkhof, F
      Magnetization transfer ratio of the spinal cord in multiple sclerosis: Relationship to atrophy and neurologic disability

      JOURNAL OF NEUROIMAGING
    26. Polman, CH; Uitdehaag, BMJ
      Regular review - Drug treatment of multiple sclerosis

      BRITISH MEDICAL JOURNAL
    27. Bot, JCJ; Barkhof, F; Nijeholt, GJLA; Bergers, E; Polman, CH; Ader, HJ; Castelijns, JA
      Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis

      EUROPEAN RADIOLOGY
    28. Nijeholt, GJLA; Uitdehaag, BMJ; Bergers, E; Castelijns, JA; Polman, CH; Barkhof, F
      Spinal cord magnetic resonance imaging in suspected multiple sclerosis

      EUROPEAN RADIOLOGY
    29. de Jong, BA; Schrijver, HM; Huizinga, TWJ; Bollen, ELEM; Polman, CH; Uitdehaag, BMJ; Kersbergen, MC; Sturk, A; Westendorp, RGJ
      Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis

      ANNALS OF NEUROLOGY
    30. van Boxel-Dezaire, AHH; van Trigt-Hoff, SCJ; Killestein, J; Schrijver, HM; van Houwelingen, JC; Polman, CH; Nagelkerken, L
      Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

      ANNALS OF NEUROLOGY
    31. Morre, SA; De Groot, CJA; Killestein, J; Meijer, CJLM; Polman, CH; Van der Valk, P; Van den Brule, AJC
      Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?

      ANNALS OF NEUROLOGY
    32. Thompson, AJ; Montalban, X; Barkhof, F; Brochet, B; Filippi, M; Miller, DH; Polman, CH; Stevenson, VL; McDonald, WI
      Diagnostic criteria for primary progressive multiple sclerosis: A positionpaper

      ANNALS OF NEUROLOGY
    33. Killestein, J; Schrijver, HM; Crusius, JBA; Perez, C; Uitdehaag, BMJ; Pena, AS; Polman, CH
      Intracellular adhesion molecule-1 polymorphisms and genetic susceptibilityto multiple sclerosis: Additional data and meta-analysis

      ANNALS OF NEUROLOGY
    34. Polman, CH; Uitdehaag, BMJ
      Drug treatment of multiple sclerosis

      WESTERN JOURNAL OF MEDICINE
    35. Kalkers, NF; de Groot, V; Lazeron, RHC; Killestein, J; Ader, HJ; Barkhof, F; Lankhorst, GJ; Polman, CH
      MS Functional Composite - Relation to disease phenotype and disability strata

      NEUROLOGY
    36. Stevenson, VL; Miller, DH; Leary, SM; Rovaris, M; Barkhof, F; Brochet, B; Dousset, V; Dousset, V; Filippi, M; Hintzen, R; Montalban, X; Polman, CH; Rovira, A; de Sa, J; Thompson, AJ
      One year follow up study of primary and transitional progressive multiple sclerosis

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    37. Nasseri, K; Uitdehaag, BMJ; van Walderveen, MAA; Ader, HJ; Polman, CH
      Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution?

      EUROPEAN JOURNAL OF NEUROLOGY
    38. Pfennings, LEMA; van der Ploeg, HM; Cohen, L; Polman, CH
      A comparison of responsiveness indices in multiple sclerosis patients

      QUALITY OF LIFE RESEARCH
    39. Cohen, L; Pouwer, F; Pfennings, LEMA; Lankhorst, GJ; van der Ploeg, HM; Polman, CH; Ader, HJ; Jonnson, A; Vleugels, L
      Factor structure of the Disability and Impact Profile in patients with multiple sclerosis

      QUALITY OF LIFE RESEARCH
    40. van Waesberghe, JHTM; Kamphorst, W; De Groot, CJA; van Walderveen, MAA; Castelijns, JA; Ravid, R; Nijeholt, GJLA; van der Valk, P; Polman, CH; Thompson, AJ; Barkhof, F
      Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability

      ANNALS OF NEUROLOGY
    41. van Walderveen, MAA; Barkhof, F; Pouwels, PJW; van Schijndel, RA; Polman, CH; Castelijns, JA
      Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy

      ANNALS OF NEUROLOGY
    42. van Boxel-Dezaire, AHH; Hoff, SCJ; van Oosten, BW; Verweij, CL; Drager, AM; Ader, HJ; van Houwelingen, JC; Barkhof, F; Polman, CH; Nagelkerken, L
      Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

      ANNALS OF NEUROLOGY
    43. Klok, AM; Buizer, AI; Polman, CH; Postmus, PE; Polak, BCP
      Intermediate uveitis and polyneuropathy in an elderly patient due to sarcoidosis

      NEURO-OPHTHALMOLOGY
    44. Rep, MHG; Schrijver, HM; van Lopik, T; Hintzen, RQ; Roos, MTL; Ader, HJ; Polman, CH; van Lier, RAW
      Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

      JOURNAL OF NEUROIMMUNOLOGY
    45. Stevenson, VL; Miller, DH; Rovaris, M; Barkhof, F; Brochet, B; Dousset, V; Dousset, V; Filippi, M; Montalban, X; Polman, CH; Rovira, A; de Sa, J; Thompson, AJ
      Primary and transitional progressive MS - A clinical and MRI cross-sectional study

      NEUROLOGY
    46. Schrijver, HM; Crusius, JBA; Uitdehaag, BMJ; Gonzalez, MAG; Kostense, PJ; Polman, CH; Pena, AS
      Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS

      NEUROLOGY
    47. Polman, CH; Miller, DH; McDonald, WI; Thompson, AJ
      Treatment recommendations for interferon-beta in multiple sclerosis

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    48. Camp, SJ; Stevenson, VL; Thompson, AJ; Miller, DH; Borras, C; Auriacombe, S; Brochet, B; Falautano, M; Filippi, M; Herisse-Dulo, L; Montalban, X; Parrcira, E; Polman, CH; De Sa, J; Langdon, DW
      Cognitive function in primary progressive and transitional progressive multiple sclerosis - A controlled study with MRI correlates

      BRAIN
    49. Pfennings, LEMA; Van der Ploeg, HM; Cohen, L; Bramsen, I; Polman, CH; Lankhorst, GJ; Vleugels, L
      A health-related quality of life questionnaire for multiple sclerosis patients

      ACTA NEUROLOGICA SCANDINAVICA
    50. Polman, CH
      Monophasic isolated inflammatory demyelinating syndromes

      FRONTIERS IN MULTIPLE SCLEROSIS, VOL 2
    51. BARKHOF F; ELTON M; LINDEBOOM J; TAS MW; SCHMIDT WF; HOMMES OR; POLMAN CH; KOK A; VALK J
      FUNCTIONAL CORRELATES OF CALLOSAL ATROPHY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS PATIENTS - A PRELIMINARY MRI STUDY

      Journal of neurology
    52. VANWAESBERGHE JHTM; VANWALDERVEEN MAA; CASTELIJNS JA; SCHELTENS P; NIJEHOLT GJL; POLMAN CH; BARKHOF F
      PATTERNS OF LESION DEVELOPMENT IN MULTIPLE-SCLEROSIS - LONGITUDINAL OBSERVATIONS WITH T1-WEIGHTED SPIN-ECHO AND MAGNETIZATION-TRANSFER MR

      American journal of neuroradiology
    53. van Waesberghe, JHTM; van Buchem, MA; Filippi, M; Castelijns, JA; Rocca, MA; van der Boom, R; Polman, CH; Barkhof, F
      MR outcome parameters in multiple sclerosis: Comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note)

      AMERICAN JOURNAL OF NEURORADIOLOGY
    54. TERBRUGGEN JP; VANDERMECHE FGA; DEJAGER AEJ; POLMAN CH
      OPHTHALMOPLEGIC AND LOWER CRANIAL NERVE VARIANTS MERGE INTO EACH OTHER AND INTO CLASSICAL GUILLAIN-BARRE-SYNDROME

      Muscle & nerve
    55. VANWALDERVEEN MAA; KAMPHORST W; SCHELTENS P; VANWAESBERGHE JHTM; RAVID R; VALK J; POLMAN CH; BARKHOF F
      HISTOPATHOLOGIC CORRELATE OF HYPOINTENSE LESIONS ON T1-WEIGHTED SPIN-ECHO MRI IN MULTIPLE-SCLEROSIS

      Neurology
    56. TAN IL; BERKHOF F; POLMAN CH; NIJEHOLT GJL; ADER HJ; SULLIVAN HC
      THE EFFECT OF LINOMIDE ON GADOLINIUM-ENHANCING LESIONS IN MULTIPLE-SCLEROSIS

      Neurology
    57. NASSERI K; TENVOORDE BJ; ADER HJ; UITDEHAAG BMJ; POLMAN CH
      LONGITUDINAL FOLLOW-UP OF CARDIOVASCULAR REFLEX RESTS IN MULTIPLE-SCLEROSIS

      Journal of the neurological sciences
    58. VANOOSTEN BW; TRUYEN L; BARKHOF F; POLMAN CH
      CHOOSING DRUG-THERAPY FOR MULTIPLE-SCLEROSIS - AN UPDATE

      Drugs
    59. VANOOSTEN BW; BARKHOF F; SCHOLTEN PET; VONBLOMBERG ME; ADER HJ; POLMAN CH
      INCREASED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA, AND NOT OF INTERFERON-GAMMA, PRECEDING DISEASE-ACTIVITY IN PATIENTS WITH MULTIPLE-SCLEROSIS

      Archives of neurology
    60. PFENNINGS LEMA; COHEN L; LANKHORST GI; POLMAN CH; VANDERPLOEG HM
      USE OF THE SF-36 AND DISABILITY AND IMPACT PROFILE IN MULTIPLE-SCLEROSIS PATIENTS

      Quality of life research
    61. VANWAESBERGHE JHT; CASTELIJNS JA; SCHELTENS P; TRUYEN L; NIJEHOLT GJLA; HOOGENRAAD FG; POLMAN CH; VALK J; BARKHOF F
      COMPARISON OF 4 POTENTIAL MR PARAMETERS FOR SEVERE TISSUE DESTRUCTIONIN MULTIPLE-SCLEROSIS LESIONS

      Magnetic resonance imaging
    62. BARKHOF F; VANWAESBERGHE JHTM; UITDEHAAG BMJ; POLMAN CH
      IBUPROFEN DOES NOT SUPPRESS ACTIVE MULTIPLE-SCLEROSIS LESIONS ON GADOLINIUM-ENHANCED MR-IMAGES

      Annals of neurology
    63. VANWAESBERGHE JHTM; CASTELIJNS JA; ROSER W; SILVER N; YOUSRY T; NIJEHOLT GJLA; ADER HJ; UITDEHAAG BMJ; RADUE EW; POLMAN CH; KAPPOS L; MILLER DH; BARKHOF F
      SINGLE-DOSE GADOLINIUM WITH MAGNETIZATION-TRANSFER VERSUS TRIPLE-DOSEGADOLINIUM IN THE MR DETECTION OF MULTIPLE-SCLEROSIS LESIONS

      American journal of neuroradiology
    64. HINTZEN RQ; POLMAN CH
      TH-CELL MODULATION IN MULTIPLE-SCLEROSIS

      Immunology today
    65. HUIZINGA TWJ; WESTENDORP RGJ; BOLLEN ELEM; KEIJSERS V; BRINKMAN BMN; LANGERMANS JAM; BREEDVELD FC; VERWEIJ CL; VANDEGAER L; DAMS L; CRUSIUS JBA; GARCIAGONZALEZ A; VANOOSTEN BW; POLMAN CH; PENA AS
      TNF-ALPHA PROMOTER POLYMORPHISMS, PRODUCTION AND SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS IN DIFFERENT GROUPS OF PATIENTS

      Journal of neuroimmunology
    66. VANOOSTEN BW; LAI M; HODGKINSON S; BARKHOF F; MILLER DH; MOSELEY IF; THOMPSON AJ; RUDGE P; MCDOUGALL A; MCLEOD JG; ADER HJ; POLMAN CH
      TREATMENT OF MULTIPLE-SCLEROSIS WITH THE MONOCLONAL ANTI-CD4 ANTIBODYCM-T412 - RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MR-MONITORED PHASE-II TRIAL

      Neurology
    67. VANOOSTEN BW; UITDEHAAG BMJ; BARKHOF F; HARTUNG HP; WAGSTAFF J; POLMAN CH
      INTERLEUKIN-2 THERAPY DOES NOT EXACERBATE MULTIPLE-SCLEROSIS

      Neurology
    68. VANWALDERVEEN M; SCHELTENS PH; VANWAESBERGHE JH; BARKHOF F; RAVID R; VALK J; POLMAN CH; KAMPHORST W
      HISTOPATHOLOGIC CORRELATE OF HYPOINTENSE LESIONS ON T1-WEIGHTED SE MR-IMAGES IN MULTIPLE-SCLEROSIS

      Neurology
    69. REP MHG; VANOOSTEN BW; ROOS MTL; ADER HJ; POLMAN CH; VANLIER RAW
      TREATMENT WITH DEPLETING CD4 MONOCLONAL-ANTIBODY RESULTS IN A PREFERENTIAL LOSS OF CIRCULATING NAIVE T-CELLS BUT DOES NOT AFFECT IFN-GAMMA SECRETING TH1 CELLS IN HUMANS

      The Journal of clinical investigation
    70. THOMPSON AJ; POLMAN CH; MILLER DH; MCDONALD WI; BROCHET B; FILIPPI M; MONTALBAN X; DESA J
      PRIMARY PROGRESSIVE MULTIPLE-SCLEROSIS

      Brain
    71. BARKHOF F; FILIPPI M; MILLER DH; SCHELTENS P; CAMPI A; POLMAN CH; COMI G; ADER HJ; LOSSEFF N; VALK J
      COMPARISON OF MRI CRITERIA AT FIRST PRESENTATION TO PREDICT CONVERSION TO CLINICALLY DEFINITE MULTIPLE-SCLEROSIS

      Brain
    72. POLMAN CH
      INTERFERON BETA-1B IN MULTIPLE-SCLEROSIS - A SEMINAR-IN-PRINT

      CLINICAL IMMUNOTHERAPEUTICS
    73. VANWAESBERGHE JHTM; CASTELIJNS JA; WEERTS JGE; NIJEHOLT GJLA; HILLEGERS JPM; POLMAN CH; BARKHOF F
      DISAPPEARANCE OF MULTIPLE-SCLEROSIS LESIONS WITH SEVERELY PROLONGED T-1 ON IMAGES OBTAINED BY A FLAIR PULSE SEQUENCE

      Magnetic resonance imaging
    74. LANKHORST GJ; JELLES F; SMITS RCF; POLMAN CH; KUIK DJ; PFENNINGS LEMA; COHEN L; VANDERPLOEG HM; KETELAER P; VLEUGELS L
      QUALITY-OF-LIFE IN MULTIPLE-SCLEROSIS - THE DISABILITY AND IMPACT PROFILE (DIP)

      Journal of neurology
    75. REP MHG; HINTZEN RQ; POLMAN CH; VANLIER RAW
      RECOMBINANT INTERFERON-BETA BLOCKS PROLIFERATION BUT ENHANCES INTERLEUKIN-10 SECRETION BY ACTIVATED HUMAN T-CELLS

      Journal of neuroimmunology
    76. VANOOSTEN BW; REP MHG; VANLIER RAW; SCHOLTEN PET; VONBLOMBERG BME; PFLUGHAUPT KW; HARTUNG HP; ADER HJ; POLMAN CH
      A PILOT-STUDY INVESTIGATING THE EFFECTS OF ORALLY-ADMINISTERED PENTOXIFYLLINE ON SELECTED IMMUNE VARIABLES IN PATIENTS WITH MULTIPLE-SCLEROSIS

      Journal of neuroimmunology
    77. TRUYEN L; VANWAESBERGHE JHTM; VANWALDERVEEN MAA; VANOOSTEN BW; POLMAN CH; HOMMES OR; ADER HJA; BARKHOF F
      ACCUMULATION OF HYPOINTENSE LESIONS (BLACK-HOLES) ON T-1 SPIN-ECHO MRI CORRELATES WITH DISEASE PROGRESSION IN MULTIPLE-SCLEROSIS

      Neurology
    78. VANOOSTEN BW; BARKHOF F; TRUYEN L; BORINGA JB; BERTELSMANN FW; VONBLOMBERG BME; WOODY JN; HARTUNG HP; POLMAN CH
      INCREASED MRI ACTIVITY AND IMMUNE ACTIVATION IN 2 MULTIPLE-SCLEROSIS PATIENTS TREATED WITH THE MONOCLONAL ANTITUMOR NECROSIS FACTOR ANTIBODY CA2

      Neurology
    79. MILLER DH; LAI HM; MOSELEY IF; GAWNECAIN M; THOMPSON AJ; VANOOSTEN B; BARKHOF F; POLMAN CH
      A COMPARISON AND METHODS FOR MEASURING MRI DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS

      Neurology
    80. UITDEHAAG BMJ; POLMAN CH; SONTROP K; DIJKSTRA CD
      THE EFFECT OF THE 21-AMINOSTEROID U74006F ON THE CLINICAL COURSE OF ACUTE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS

      Journal of the neurological sciences
    81. POLMAN CH; HARTUNG HP
      THE TREATMENT OF MULTIPLE-SCLEROSIS - CURRENT AND FUTURE

      Current opinion in neurology
    82. REP MHG; HINTZEN RQ; POLMAN CH; VANLIER RAW
      IN-VITRO IMMUNOMODULATING EFFECTS OF INTERFERON-BETA

      Journal of cellular biochemistry
    83. TAS MW; BARKHOL F; VANWALDERVEEN MAA; POLMAN CH; HOMMES OR; VALK J
      THE EFFECT OF GADOLINIUM ON THE SENSITIVITY AND SPECIFICITY OF MR IN THE INITIAL DIAGNOSIS OF MULTIPLE-SCLEROSIS

      American journal of neuroradiology
    84. HINTZEN RQ; FISZER U; FREDRIKSON S; REP M; POLMAN CH; VANLIER RAW; LINK H
      ANALYSIS OF CD27 SURFACE EXPRESSION ON T-CELL SUBSETS IN MS PATIENTS AND CONTROL INDIVIDUALS

      Journal of neuroimmunology
    85. CRUSIUS JBA; PENA AS; VANOOSTEN BW; BIOQUE G; GARCIA A; DIJKSTRA CD; POLMAN CH
      INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AND MULTIPLE-SCLEROSIS

      Lancet
    86. VANWALDERVEEN MAA; BARKHOF F; HOMMES OR; POLMAN CH; TOBI H; FREQUIN STFM; VALK J
      CORRELATING MRI AND CLINICAL-DISEASE ACTIVITY IN MULTIPLE-SCLEROSIS -RELEVANCE OF HYPOINTENSE LESIONS ON SHORT-TR SHORT-TE (T-1-WEIGHTED) SPIN-ECHO IMAGES

      Neurology
    87. BARKHOF F; FILIPPI M; HORSFIELD MA; LOSSEFF N; TAS MW; COMI GC; MILLER DH; VANWALDERVEEN MAA; CAMPI A; HOMMES OR; POLMAN CH; KINGSLEY D; VALK J
      TOWARDS SPECIFIC MAGNETIC-RESONANCE-IMAGING CRITERIA IN THE EARLY DIAGNOSIS OF MULTIPLE-SCLEROSIS

      Neurology
    88. PURBA JS; RAADSHEER FC; HOFMAN MA; RAVID R; POLMAN CH; KAMPHORST W; SWAAB DF
      INCREASED NUMBER OF CORTICOTROPIN-RELEASING HORMONE EXPRESSING NEURONS IN THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS OF PATIENTS WITH MULTIPLE-SCLEROSIS

      Neuroendocrinology
    89. VANNOORT JM; VANSECHEL AC; BAJRAMOVIC JJ; ELOUAGMIRI M; POLMAN CH; LASSMANN H; RAVID R
      THE SMALL HEAT-SHOCK PROTEIN ALPHA-B-CRYSTALLIN AS CANDIDATE AUTOANTIGEN IN MULTIPLE-SCLEROSIS

      Nature
    90. VANOOSTEN BW; TRUYEN L; BARKHOF F; POLMAN CH
      MULTIPLE-SCLEROSIS THERAPY - A PRACTICAL GUIDE

      Drugs
    91. LUCAS CJ; VANSECHEL AC; ELQUAGMIRI M; POLMAN CH; RAVID R; VANNOORT JM
      HUMAN T-CELLS TO CNS MYELIN FOCUS ON MINOR PROTEIN-COMPONENTS

      The FASEB journal
    92. VANNOORT JM; VANSECHEL AC; ELOUAGMIRI M; LUCAS CJ; POLMAN CH; RAVID R
      HUMAN T-CELLS RESPONSIVE TO CNS MYELIN FOCUS ON A MINOR PROTEIN-COMPONENT

      Journal of cellular biochemistry
    93. DIJKSTRA CD; VANDERVOORT ER; DEGROOT CJA; HUITINGA I; UITDEHAAG BMJ; POLMAN CH; BERKENBOSCH F
      THERAPEUTIC EFFECT OF THE D-2-DOPAMINE AGONIST BROMOCRIPTINE ON ACUTEAND RELAPSING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS

      Psychoneuroendocrinology
    94. REP MHG; HINTZEN RQ; POLMAN CH; VANLIER RAW
      FUNCTIONAL DEFECTS IN PERIPHERAL-BLOOD T-CELLS OF MULTIPLE-SCLEROSIS PATIENTS - DIMINISHED IN-VITRO RESPONSIVENESS IN ACCESSORY CELL-DEPENDENT ACTIVATION SYSTEMS

      Journal of neuroimmunology
    95. POLMAN CH; KOETSIER JC
      CLADRIBINE TREATMENT OF MULTIPLE-SCLEROSIS

      Lancet
    96. SMITS RCF; EMMEN HH; BERTELSMANN FW; KULIG BM; VANLOENEN AC; POLMAN CH
      THE EFFECTS OF 4-AMINOPYRIDINE ON COGNITIVE FUNCTION IN PATIENTS WITHMULTIPLE-SCLEROSIS - A PILOT-STUDY

      Neurology
    97. POLMAN CH; SMITS RCF; BERTELSMANN FW; VANLOENEN AC; EMMEN HH; KULIG BM
      THE EFFECTS OF 4-AMINOPYRIDINE ON COGNITIVE FUNCTION OF MS PATIENTS

      Neurology
    98. VANWALDERVEEN MAA; TAS MW; BARKHOF F; POLMAN CH; FREQUIN STFM; HOMMES OR; VALK J
      MAGNETIC-RESONANCE EVALUATION OF DISEASE-ACTIVITY DURING PREGNANCY INMULTIPLE-SCLEROSIS

      Neurology
    99. POLMAN CH; BERTELSMANN FW; VANLOENEN AC; KOETSIER JC
      4-AMINOPYRIDINE IN THE TREATMENT OF PATIENTS WITH MULTIPLE-SCLEROSIS - LONG-TERM EFFICACY AND SAFETY

      Archives of neurology
    100. POLMAN CH; BERTELSMANN FW; DEWAAL R; VANDIEMEN HAM; UITDEHAAG BMJ; VANLOENEN AC; KOETSIER JC
      4-AMINOPYRIDINE IS SUPERIOR TO 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF PATIENTS WITH MULTIPLE-SCLEROSIS

      Archives of neurology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/08/20 alle ore 18:51:24